tiprankstipranks
Advertisement
Advertisement

CTSO Stock Latest News

Cytosorbents Faces Nasdaq Compliance and Delisting Risk
Company AnnouncementsCytosorbents Faces Nasdaq Compliance and Delisting Risk
14d ago
8K
CTSO
CytoSorbents Advances FDA Pathway for DrugSorb Programs
PremiumCompany Announcements
CytoSorbents Advances FDA Pathway for DrugSorb Programs
26d ago
8K
CTSO
Cytosorbents Earnings Call Balances Progress and Pressure
PremiumCompany Announcements
Cytosorbents Earnings Call Balances Progress and Pressure
2M ago
CTSO
Cytosorbents Earnings Call Balances Progress And Pressure
PremiumCompany Announcements
Cytosorbents Earnings Call Balances Progress And Pressure
2M ago
CTSO
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
PremiumThe Fly
CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year
2M ago
CTSO
CTSO Earnings this Week: How Will it Perform?
PremiumPre-EarningsCTSO Earnings this Week: How Will it Perform?
3M ago
CTSO
CytoSorbents Receives Nasdaq Extension to Regain Compliance
Premium
Company Announcements
CytoSorbents Receives Nasdaq Extension to Regain Compliance
4M ago
8K
CTSO
Cytosorbents’ Earnings Call Balances Progress and Risk
Premium
Company Announcements
Cytosorbents’ Earnings Call Balances Progress and Risk
4M ago
CTSO
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
PremiumRatings
CytoSorbents: Neutral Stance as U.S. DrugSorb-ATR Opportunity Offsets Near-Term Execution and Regulatory Risks
4M ago
CTSO
CytoSorbents Narrows Losses Amid Strategic Shift and Growth
PremiumCompany Announcements
CytoSorbents Narrows Losses Amid Strategic Shift and Growth
4M ago
8K
CTSO
CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year
PremiumThe Fly
CytoSorbents reports Q4 adjusted EPS (7c) vs. (3c) last year
4M ago
CTSO
CTSO Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CTSO Upcoming Earnings Report: What to Expect?
4M ago
CTSO
CytoSorbents sees Q4 revenue $9.2M, consensus $9.85M
PremiumThe FlyCytoSorbents sees Q4 revenue $9.2M, consensus $9.85M
6M ago
CTSO
CytoSorbents sees FY25 revenue $37M, consensus $37.67M
Premium
The Fly
CytoSorbents sees FY25 revenue $37M, consensus $37.67M
6M ago
CTSO
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges
Premium
Company Announcements
Cytosorbents Corp’s Earnings Call: Growth Amid Challenges
8M ago
CTSO
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
PremiumThe Fly
CytoSorbents price target lowered to 75c from $1 at H.C. Wainwright
8M ago
CTSO
CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances
PremiumCompany Announcements
CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances
8M ago
CTSO
CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
PremiumThe Fly
CytoSorbents reports Q3 adjusted EPS (4c), consensus (5c)
8M ago
CTSO
CytoSorbents implemented workforce and cost reduction program
PremiumThe Fly
CytoSorbents implemented workforce and cost reduction program
8M ago
CTSO
CTSO Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsCTSO Upcoming Earnings Report: What to Expect?
8M ago
CTSO
Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?
Premium
Company Announcements
Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?
9M ago
CTSO
CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update
Premium
Company Announcements
CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update
9M ago
CTSO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >